284007
Health-related quality of life in elderly survivors of uncommon cancers
METHODS: Using data linked from the Surveillance Epidemiology and End Results United States cancer registry system and the Centers for Medicaid & Medicare Services Medicare Health Outcomes Survey (MHOS), we report HRQOL physical and mental health component summary scores (PCS and MCS) estimated using the Veterans RAND 12-item survey. Our analytic sample included 9550 individuals 65 and older who were diagnosed with the previously listed cancers, enrolled in Medicare Advantage plans and responded to the MHOS between 1998-2007.
RESULTS: Across all cancer sites, physical summary scores were clinically and statistically significantly lower from population normative values, ranging from 30 (SD =11) for multiple myeloma to 41 for melanoma (SD=12). In contrast, across the disease sites, mean MCS scores were generally preserved, with scores ranging from 47 (SD=12) for pancreatic cancer to 53 (SD=9) for melanoma.
CONCLUSION: Documenting HRQOL levels in elderly cancer survivors is an important first step in identifying sub-populations most likely to benefit from interventions. Ongoing PRO surveillance is necessary to create more comprehensive assessments of elderly patient experiences and suggest more patient-centered interventions.
Public health or related nursing
Public health or related research
Social and behavioral sciences
Learning Objectives:
Compare population-based health-related quality of life mental and physical component scores in elderly survivors of uncommon cancers and elderly individuals without a history of cancer.
Keywords: Cancer, Quality of Life
Qualified on the content I am responsible for because: Because I am an epidemiologist and researcher who specializes in patient-reported outcomes from survey data. I am also the scientific lead on the data linkage used for these data, the SEER-MHOS data linkage.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.